Johnson & Johnson seeks authorization for booster doses of its vaccine

Pharmaceutical group Johnson & Johnson announced on Tuesday that it had submitted data to the United States Medicine Agency (FDA) for approval for a booster injection in adults of its single-dose vaccine against COVID-19. These data include the results of a clinical study in which a second dose was injected approximately two months (56 days) after the first showed 94% efficacy against symptomatic (moderate to severe) cases in the United States, and 100% against severe cases 14 days after this second injection, the company said in a press release. A second dose is injected six months after the antibody levels were observed “by nine,” according to another “J&J” study, and “up to twelve” four weeks after the booster. The American group assures that the vaccine, taken as a single dose or booster dose, is generally well tolerated by patients. The FDA, for its part, indicated that committees of experts would meet on October 14 and 15 to study applications for authorization from Johnson & Johnson and Company Moderne. “We look forward to speaking with the FDA and other health officials regarding the booster dose,” said Mathai Maimon, research and development manager at Jensen, a pharmaceutical subsidiary of Johnson & Johnson. “At the same time, we believe that a single-dose vaccine against COVID-19, which provides robust and long-term protection, is an important contribution to immunizing the world’s population,” he said. The single-dose vaccine has received emergency authorization in the United States since February 2021 and has been administered to 15 million people, far fewer than the two-dose vaccines from Pfizer/BioNTech (229.3 million) and Moderna (152 million). Is. The United States has already authorized a third dose of the Pfizer/BioNTech vaccine for people 65 years of age and older and certain people who have health conditions or are specifically exposed to the virus. at risk”. People who are immunocompromised may also receive a booster dose of Moderna’s vaccine. The theme of the third dose at the heart of the new US vaccine strategy launched in September has revived the issue of disparities between rich and poor countries, while access to the first dose of the vaccine remains very limited in some areas of the country. world, especially in Africa.

See also  7 billion countries oppose it

You May Also Like

About the Author: Hanley Mallin

Internet geek. Wannabe bacon enthusiast. Web trailblazer. Music maven. Entrepreneur. Pop culture fan.

Leave a Reply

Your email address will not be published.